Tapentadol, Buprenorphine, and Levorphanol for the Treatment of Neuropathic Pain: a Systematic Review

Erosa, Samantha C; Haffey, Paul Ryan; Mehta, Neel; Gulati, Amitabh

doi:10.1007/s11916-020-00934-z

Cited by 9 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Good analgesic effects are also brought by a splanchnicectomy—surgical, laparoscopic removal of the ventral sympathetic ganglia. The systematic review by Erosa et al presents available studies using the atypical opioids tapentadol, buprenorphine, and levophanol in the treatment of neuropathic pain [ 39 ]. A total of ten out of 1619 studies were included in the review.…”

Section: Resultsmentioning

confidence: 99%

Quality of Life in Patients with Pancreatic Cancer—A Literature Review

Cipora

Czerw

Partyka

et al. 2023

IJERPH

View full text Add to dashboard Cite

Pancreatic cancer is the malignant disease with the highest mortality rate, and it ranks third in the world after lung and colon cancer. Identified factors that increase the risk of developing pancreatic cancer include chronic pancreatitis, radiation therapy to the pancreatic area due to another cancer, diabetes mellitus, obesity, smoking, and age. The objective of this study was to present the current state of knowledge on the quality of life of patients diagnosed with pancreatic cancer, factors that determine QoL, and ways of coping with the disease. The low curability and low survival rates of pancreatic cancer significantly affect the quality of life of patients, often in the form of significant deterioration, especially in terms of mental changes, cognitive functions, and coping with the disease. Cognitive decline with comorbid depression is also typical for patients with this type of cancer. Research has shown that the health-related quality of life of patients with pancreatic cancer is low, so further research is needed to improve the situation in this area.

show abstract

Section: Resultsmentioning

confidence: 99%

Quality of Life in Patients with Pancreatic Cancer—A Literature Review

Cipora

Czerw

Partyka

et al. 2023

IJERPH

View full text Add to dashboard Cite

show abstract

“…BUP also shows protective effects against the development of myonecrotic disease specific to Clostridium perfringens -mediated myonecrosis [ 35 ]. If therapy with BUP fails for some reason or is not possible, treatment with another atypical opioid such as tapentadol may be initiated [ 36 ]. Tapentadol has a lower risk of opioid-related side effects, such as constipation and nausea, which is of high clinical importance in the MPX patient population.…”

Section: Clinical Nociceptive Manifestations During the Current Outbreakmentioning

confidence: 99%

Integrated Analgesic Care in the Current Human Monkeypox Outbreak: Perspectives on an Integrated and Holistic Approach Combining Old Allies with Innovative Technologies

2022

View full text Add to dashboard Cite

Monkeypox (MPX) is a zoonotic infection caused by an orthopoxvirus that is endemic to Central and Western Africa. The MPX virus is a part of the same family of viruses as the variola virus, which causes smallpox. Since May 2022, there has been a global increase in the incidence of MPX infections in multiple countries where the illness is not usually prevalent. A growing number of publications have emphasized on the need for increased awareness among all health professionals for the rapid recognition and diagnosis of this disease and for proper public health measures. However, atypical presentations and occurrence of uncommon symptoms receive less than the desired attention. More specifically, MPX infection related nociceptive symptoms are currently underexposed. Nevertheless, reports from the current outbreak have revealed that (severe) pain is one of the major causes for distress and even hospitalization in these patients. As for all serious pain conditions, an integrated, multidisciplinary, and holistic approach is indicated. This approach should be multimodal and include non-pharmacological therapies alongside pharmacological approaches. Health care professionals should be aware of available alternatives when first choice analgesic therapies fail. Protocols for identification of pain type and prolonged monitoring of clinical status should be implemented to improve patient well-being during acute infection, but also prevent chronic nociceptive syndromes.

show abstract

“…Tapentadol, tramadol, buprenorphine, levorphanol, and methadone are atypical opioids. [109] Tapentadol exhibits additional norepinephrine reuptake inhibition, whereas tramadol exhibits additional serotonin and norepinephrine reuptake inhibition. These additional mechanisms activate the descending inhibitory pathways, complement, and potentiate the μ-opioid receptor activation, contributing to an opioidsparing effect.…”

Section: Tcasmentioning

confidence: 99%

“…[117] Buprenorphine is an atypical opioid: A partial agonist at the μ-opioid receptor, agonist at the δ-opioid and opioid receptor-like 1 (ORL-1) receptor and a weak antagonist at the κ-opioid receptor. [109] Levorphanol is another atypical opioid: Agonist at the μ-opioid, the δ-opioid, and the κ-opioid receptors; antagonist at the NMDA receptors and having an SNRI like effect. A recent systematic review that evaluated the effects of atypical opioids including tapentadol, buprenorphine and levorphanol in patients with neuropathic pain observed that the evidence is strong for tapentadol, whereas it is weak for buprenorphine and levorphanol.…”

Section: Tcasmentioning

confidence: 99%

Pharmacotherapy of Painful Diabetic Neuropathy: A Clinical Update

James¹

2022

Sisli Etfal

View full text Add to dashboard Cite

T he current global prevalence of diabetes mellitus (DM) among adults (aged 20-70 years) is 537 million (one in every ten adults) that is expected to raise to 643 million by the year 2030, and 783 million by the year 2045. [1] The increasing prevalence of DM has led to a rise in chronic diabetic complications. Diabetic peripheral neuropathies (DPNs) are the most common chronic complications of diabetes. [2] Among these, the distal symmetric polyneuropa-thy (DSPN) is the most prevalent form which may affect up to 50% of patients with type 2 DM (T2DM) after 10 years of the disease, and at least 20% with type 1 DM (T1DM) after 20 years of the disease. [3] Furthermore, nearly 10-15% of newly diagnosed T2DM may have DSPN.Although a vast majority of patients with DPN may remain pain-free, painful DPN (PDPN) is estimated to affect 6-34% of all patients with DM. [4] The disease burden from PDPN The rising prevalence of diabetes mellitus (DM) leads on to an increase in chronic diabetic complications. Diabetic peripheral neuropathies (DPNs) are common chronic complications of diabetes. Distal symmetric polyneuropathy is the most prevalent form. Most patients with DPN will remain pain-free; however, painful DPN (PDPN) occurs in 6-34% of all DM patients and is associated with reduced health-related-quality-of-life and substantial economic burden. Symptomatic treatment of PDPN and diabetic autonomic neuropathy is the key treatment goals. Using certain patient related characteristics, subjects with PDPN can be stratified and assigned targeted therapies to produce better pain outcomes. The aim of this review is to discuss the various pathogenetic mechanisms of DPN with special reference to the mechanisms leading to PDPN and the various pharmacological and non-pharmacological therapies available for its management. Recommended pharmacological therapies include anticonvulsants, antidepressants, opioid analgesics, and topical medications.

show abstract

Tapentadol, Buprenorphine, and Levorphanol for the Treatment of Neuropathic Pain: a Systematic Review

Cited by 9 publications

References 45 publications

Quality of Life in Patients with Pancreatic Cancer—A Literature Review

Quality of Life in Patients with Pancreatic Cancer—A Literature Review

Integrated Analgesic Care in the Current Human Monkeypox Outbreak: Perspectives on an Integrated and Holistic Approach Combining Old Allies with Innovative Technologies

Pharmacotherapy of Painful Diabetic Neuropathy: A Clinical Update

Contact Info

Product

Resources

About